November 9, 2018—The FDA recently announced its approval of Dsuvia, a sublingual formulation of sufentanil that is delivered through a disposable, pre-filled, single-dose applicator. It has a unique ability to provide high-level pain relief in a short time without the need for IV access. This medication is 10 times more potent than fentanyl and 1,000 times more potent than morphine.
FDA Commissioner Scott Gottlieb, MD, has released a statement that discusses concerns raised regarding the approval of this new medication.
The guidelines suggested here are not rules, do not constitute legal advice, and do not ensure a successful outcome. The ultimate decision regarding the appropriateness of any treatment must be made by each healthcare provider considering the circumstances of the individual situation and in accordance with the laws of the jurisdiction in which the care is rendered.